Hif1a Cancer Research Results

Hif1a, HIF1α/HIF1a: Click to Expand ⟱
Source:
Type:
Hypoxia-Inducible-Factor 1A (HIF1A gene, HIF1α, HIF-1α protein product)
-Dominantly expressed under hypoxia(low oxygen levels) in solid tumor cells
-HIF1A induces the expression of vascular endothelial growth factor (VEGF)
-High HIF-1α expression is associated with Poor prognosis
-Low HIF-1α expression is associated with Better prognosis

-Functionally, HIF-1α is reported to regulate glycolysis, whilst HIF-2α regulates genes associated with lipoprotein metabolism.
-Cancer cells produce HIF in response to hypoxia in order to generate more VEGF that promote angiogenesis

Key mediators of aerobic glycolysis regulated by HIF-1α.
-GLUT-1 → regulation of the flux of glucose into cells.
-HK2 → catalysis of the first step of glucose metabolism.
-PKM2 → regulation of rate-limiting step of glycolysis.
-Phosphorylation of PDH complex by PDK → blockage of OXPHOS and promotion of aerobic glycolysis.
-LDH (LDHA): Rapid ATP production, conversion of pyruvate to lactate;

HIF-1α Inhibitors:
-Curcumin: disruption of signaling pathways that stabilize HIF-1α (ie downregulate).
-Resveratrol: downregulate HIF-1α protein accumulation under hypoxic conditions.
-EGCG: modulation of upstream signaling pathways, leading to decreased HIF-1α activity.
-Emodin: reduce HIF-1α expression. (under hypoxia).
-Apigenin: inhibit HIF-1α accumulation.
Stroke, Cerebral Ischemic Stroke: Click to Expand ⟱
Ischemic stroke is also called brain ischemia and cerebral ischemia. Ischemia is the medical term for "lack of blood supply."

Quick Reference

Mechanism Top Compounds
Blood flow / anti-thrombotic support Aspirin, Ginkgo biloba, Panax notoginseng, Salvia miltiorrhiza
Membrane repair / cholinergic support Citicoline, Alpha-GPC
Antioxidant / ROS control EGCG, Curcumin, Quercetin, Tocotrienols
Anti-inflammatory / NF-κB / cytokines Curcumin, Luteolin, Baicalin
Mitochondrial protection Resveratrol, Citicoline
BBB protection Rosmarinic acid, Astragaloside IV

Stroke/Product Table - Dose + Practical Therapeutic Index

Compound Class Primary Mechanisms Key Stroke Effects Evidence Level Phase Utility Human Dose Range Approx. HED mg/kg/day Practical Therapeutic Index
Aspirin NSAID / anti-platelet COX-1 inhibition; ↓ thromboxane A2; ↓ platelet aggregation Reduces recurrent ischemic stroke risk Strong clinical; standard of care Acute + prevention 81–325 mg/day ~1.2–4.6 mg/kg/day for 70 kg adult High, but bleeding-risk limited
Citicoline / CDP-choline Choline donor Membrane repair; ↑ phosphatidylcholine; ↓ free fatty acid release May support neurological and cognitive recovery Clinical; mixed acute results, better recovery/cognition signal Recovery 500–2000 mg/day ~7–29 mg/kg/day for 70 kg adult Moderate–High
Alpha-GPC Choline donor ↑ acetylcholine; phospholipid support May support post-stroke cognition Clinical; moderate support Recovery 300–1200 mg/day ~4–17 mg/kg/day for 70 kg adult Moderate; TMAO concern
Ginkgo biloba Herbal extract Cerebral blood flow; antioxidant; anti-platelet May support perfusion and cognition Clinical + preclinical Recovery 120–240 mg/day standardized extract ~1.7–3.4 mg/kg/day Moderate; bleeding interaction caution
Panax notoginseng / PNS Saponins Anti-thrombotic; perfusion; anti-inflammatory Improved blood flow/recovery measures in some studies Clinical mainly China + preclinical Acute + recovery Variable extract-dependent Study-specific; often preclinical HED needed Moderate; bleeding interaction caution
Salvia miltiorrhiza / Danshen Herbal extract Microcirculation; vascular protection; anti-platelet May support vascular recovery Clinical mainly China + preclinical Acute + recovery Variable extract/root equivalent Study-specific Moderate; bleeding interaction caution
Baicalin Flavonoid Anti-inflammatory; anti-apoptotic; antioxidant Neuroprotection in ischemic injury models Preclinical + limited clinical Acute No established stroke dose Preclinical HED only Moderate–Low
Curcumin Polyphenol ↓ NF-κB; ↓ cytokines; antioxidant Reduced infarct size/inflammation in models Strong preclinical Acute + recovery 500–2000 mg/day bioavailable form ~7–29 mg/kg/day Moderate; bioavailability limited
Resveratrol Polyphenol SIRT1; mitochondrial protection; anti-apoptotic Reduced apoptosis/infarct injury in models Strong preclinical Acute + recovery 100–500 mg/day ~1.4–7.1 mg/kg/day Moderate; bioavailability limited
EGCG Catechin ROS scavenging; vascular protection Reduced neuronal injury in models Strong preclinical Acute 200–400 mg/day EGCG ~2.9–5.7 mg/kg/day Moderate; liver-dose caution
Quercetin Flavonoid Antioxidant; anti-inflammatory; anti-edema Reduced edema/infarct size in models Strong preclinical Acute 500–1000 mg/day ~7–14 mg/kg/day Moderate
Melatonin Indoleamine Mitochondrial antioxidant; anti-inflammatory Reduced ischemia-reperfusion injury in models Preclinical + limited clinical interest Acute + recovery 3–10 mg/day ~0.04–0.14 mg/kg/day Moderate–High
Tocotrienols Vitamin E subtype Lipid antioxidant; membrane protection Neuroprotection in ischemic models Preclinical + limited clinical Acute 100–300 mg/day ~1.4–4.3 mg/kg/day Moderate
Luteolin Flavonoid NF-κB / Nrf2 / PI3K-Akt modulation Reduced inflammation/neuroprotection in models Strong preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Ferulic acid Phenolic acid Antioxidant; vasodilation; vascular protection Improved blood flow/reduced injury in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Rosmarinic acid Phenolic acid BBB protection; antioxidant; anti-inflammatory Reduced BBB disruption in models Preclinical Acute No established stroke dose Preclinical HED only Low–Moderate
Berberine Alkaloid AMPK activation; metabolic/vascular protection Neuroprotection in ischemia models Preclinical Prevention + recovery 500–1500 mg/day ~7–21 mg/kg/day Moderate; interaction caution
Huperzine A Alkaloid AChE inhibition; cholinergic support May support cognitive recovery Preclinical + cognitive clinical context Recovery 100–200 µg/day ~0.001–0.003 mg/kg/day Low–Moderate; narrow cholinergic tolerance
Honokiol Lignan Mitochondrial protection; anti-inflammatory Reduced ischemic neuronal injury in models Preclinical Acute + recovery No established stroke dose Preclinical HED only Low
HED: Human Equilvalent Dose
Scientific Papers found: Click to Expand⟱
2660- AL,    Allicin: A review of its important pharmacological activities
- Review, AD, NA - Review, Var, NA - Review, Park, NA - Review, Stroke, NA
*Inflam↓, AntiCan↑, *antiOx↑, *cardioP↑, *hepatoP↑, *BBB↑, *Half-Life↝, *H2S↑, *BP↓, *neuroP↑, *cognitive↑, *neuroP↑, *ROS↓, *GutMicro↑, *LDH↓, *ROS↓, *lipid-P↓, *antiOx↑, *other↑, *PI3K↓, *Akt↓, *NF-kB↓, *NO↓, *iNOS↓, *PGE2↓, *COX2↓, *IL6↓, *TNF-α↓, *MPO↓, *eff↑, *NRF2↑, *Keap1↓, *TBARS↓, *creat↓, *LDH↓, *AST↓, *ALAT↓, *MDA↓, *SOD↑, *GSH↑, *GSTs↑, *memory↑, chemoP↑, IL8↓, Cyt‑c↑, Casp3↑, Casp8↑, Casp9↑, Casp12↑, p38↑, Fas↑, P53↑, P21↑, CHK1↓, CycB/CCNB1↓, GSH↓, ROS↑, TumCCA↑, Hif1a↓, Bcl-2↓, VEGF↓, TumCMig↓, STAT3↓, VEGFR2↓, p‑FAK↓,
2626- Ba,    Molecular targets and therapeutic potential of baicalein: a review
- Review, Var, NA - Review, AD, NA - Review, Stroke, NA
AntiCan↓, *neuroP↑, *cardioP↑, *hepatoP↑, *RenoP↑, TumCCA↑, CDK4↓, cycD1/CCND1↓, cycE/CCNE↑, BAX↑, Bcl-2↓, VEGF↓, Hif1a↓, cMyc↓, NF-kB↓, ROS↑, BNIP3↑, *neuroP↑, *cognitive↑, *NO↓, *iNOS↓, *COX2↓, *PGE2↓, *NRF2↑, *p‑AMPK↑, *Ferroptosis↓, *lipid-P↓, *ALAT↓, *AST↓, *Fas↓, *BAX↓, *Apoptosis↓,
6002- CGA,    Chlorogenic Acid: A Systematic Review on the Biological Functions, Mechanistic Actions, and Therapeutic Potentials
- Review, Var, NA - Review, Diabetic, NA - Review, AD, NA - Review, Park, NA - Review, Stroke, NA
*neuroP↑, *Inflam↓, *antiOx↑, *cardioP↑, *NRF2↑, *AMPK↑, *SOD↑, *Catalase↑, *GSH↑, *GPx↑, *ROS↓, *TNF-α↓, *IL6↓, *NF-kB↓, *COX2↓, *glucose↓, *TRPC1↓, *Ca+2↓, *HO-1↑, *NF-kB↓, *PPARα↝, *Hif1a↓, *JNK↓, *BP↓, *AntiDiabetic↑, *hepatoP↑, *TLR4↓, *NRF2↑, *Casp↓, *neuroP↑, *Aβ↓, *LDH↓, *MDA↓, *memory↑, *AChE↓, *eff↑, EMT↝, N-cadherin↓, E-cadherin↑, TumCCA↑, ROS↑, p‑P53↑, HO-1↑, NRF2↑, ChemoSen↑, mtDam↑, Casp3↑, Casp9↑, PARP↑, Bax:Bcl2↑, TumCG↓, cycD1/CCND1↓, cMyc↓, CDK2↓, mitResp↓, Glycolysis↓, Hif1a↓, PCNA↓, p‑GSK‐3β↓, VEGF↓, PI3K↓, Akt↓, mTOR↓, OS↑,

Showing Research Papers: 1 to 3 of 3

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 3

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

GSH↓, 1,   HO-1↑, 1,   NRF2↑, 1,   ROS↑, 3,  

Mitochondria & Bioenergetics ⓘ

mitResp↓, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis ⓘ

cMyc↓, 2,   Glycolysis↓, 1,  

Cell Death ⓘ

Akt↓, 1,   BAX↑, 1,   Bax:Bcl2↑, 1,   Bcl-2↓, 2,   Casp12↑, 1,   Casp3↑, 2,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 1,   Fas↑, 1,   p38↑, 1,  

Autophagy & Lysosomes ⓘ

BNIP3↑, 1,  

DNA Damage & Repair ⓘ

CHK1↓, 1,   P53↑, 1,   p‑P53↑, 1,   PARP↑, 1,   PCNA↓, 1,  

Cell Cycle & Senescence ⓘ

CDK2↓, 1,   CDK4↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 2,   cycE/CCNE↑, 1,   P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State ⓘ

EMT↝, 1,   p‑GSK‐3β↓, 1,   mTOR↓, 1,   PI3K↓, 1,   STAT3↓, 1,   TumCG↓, 1,  

Migration ⓘ

E-cadherin↑, 1,   p‑FAK↓, 1,   N-cadherin↓, 1,   TumCMig↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 3,   VEGF↓, 3,   VEGFR2↓, 1,  

Immune & Inflammatory Signaling ⓘ

IL8↓, 1,   NF-kB↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↑, 1,  

Functional Outcomes ⓘ

AntiCan↓, 1,   AntiCan↑, 1,   chemoP↑, 1,   OS↑, 1,  
Total Targets: 52

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 3,   Catalase↑, 1,   Ferroptosis↓, 1,   GPx↑, 1,   GSH↑, 2,   GSTs↑, 1,   HO-1↑, 1,   Keap1↓, 1,   lipid-P↓, 2,   MDA↓, 2,   MPO↓, 1,   NRF2↑, 4,   ROS↓, 3,   SOD↑, 2,   TBARS↓, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 2,   AMPK↑, 1,   p‑AMPK↑, 1,   glucose↓, 1,   H2S↑, 1,   LDH↓, 3,   PPARα↝, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↓, 1,   BAX↓, 1,   Casp↓, 1,   Fas↓, 1,   Ferroptosis↓, 1,   iNOS↓, 2,   JNK↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

PI3K↓, 1,  

Migration ⓘ

Ca+2↓, 1,   TRPC1↓, 1,  

Angiogenesis & Vasculature ⓘ

Hif1a↓, 1,   NO↓, 2,  

Barriers & Transport ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 3,   IL6↓, 2,   Inflam↓, 2,   NF-kB↓, 3,   PGE2↓, 2,   TLR4↓, 1,   TNF-α↓, 2,  

Synaptic & Neurotransmission ⓘ

AChE↓, 1,  

Protein Aggregation ⓘ

Aβ↓, 1,  

Drug Metabolism & Resistance ⓘ

eff↑, 2,   Half-Life↝, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   AST↓, 2,   BP↓, 2,   creat↓, 1,   GutMicro↑, 1,   IL6↓, 2,   LDH↓, 3,  

Functional Outcomes ⓘ

AntiDiabetic↑, 1,   cardioP↑, 3,   cognitive↑, 2,   hepatoP↑, 3,   memory↑, 2,   neuroP↑, 6,   RenoP↑, 1,  
Total Targets: 62

Scientific Paper Hit Count for: Hif1a, HIF1α/HIF1a
1 Allicin (mainly Garlic)
1 Baicalein
1 Chlorogenic acid
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:36  Cells:%  prod#:%  Target#:143  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page